Monday, February 23, 2026

In Detail Full day, Monday, February 23, 2026, Timezone: America/Chicago

Gilead to acquire cell therapy manufacturer for $7.8B

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.

Justice Department sues OhioHealth over alleged anticompetitive insurer contracts

Sydney Halleman / healthcaredive - The DOJ filed a lawsuit last week accusing OhioHealth of leveraging its market power to force insurers to include its providers in their networks.

AI Summary: The Justice Department filed a civil antitrust suit accusing OhioHealth of using its market dominance to force insurers to include all system hospitals in provider networks, allegedly blocking lower‑cost plan options and harming competition. The case seeks to stop contract practices deemed exclusionary and could prompt changes in hospital‑insurer negotiation tactics.

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin

esmo - Findings from the KEYNOTE-905/EV-303 study

AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.

Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.